ReviewArchives of biochemistry and biophysics2022
Oxidative modification of HDL by lipid aldehydes impacts HDL function.
Review in Archives of biochemistry and biophysics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease.European journal of medical research · 2025 · on this mapPooled it
- Beyond Biomimetics: Pathology-Informed Engineering Rescues Reconstituted HDL From Inflammatory Dysfunction for Sepsis Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Evaluation of High-Density Lipoprotein Capacity to Acquire Free Cholesterol From Triglyceride-Rich Lipoproteins During Reverse Remnant-Cholesterol Transport in Familial Hypercholesterolemia.Endocrinology, diabetes & metabolism · 2026Article
- Machine learning evaluation of the discriminative ability of Castelli Risk Index-I and other non-traditional lipid indices for sarcopenia: a cross-sectional study based on CHARLS.Lipids in health and disease · 2026Article
- HDL function and composition in atherothrombotic cardiovascular disease with very high HDL-C.European journal of clinical investigation · 2026Article
- HDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications.Journal of clinical medicine · 2025Review
- Early Cardiovascular and Metabolic Benefits of rhGH Therapy in Adult Patients with Severe Growth Hormone Deficiency: Impact on Oxidative Stress Parameters.International journal of molecular sciences · 2025Article
- Bibliometric analysis of studies on the lipid management of coronary heart disease from 2014 to 2023.Frontiers in cardiovascular medicine · 2025Review
- Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression.Molecular & cellular proteomics : MCP · 2024Article
- Urate Levels as a Predictor of the Prevalence and Level of Cardiovascular Risk Factors: An Identificación de La PoBlación Española de Riesgo Cardiovascular y Renal Study.Biomolecules · 2024Article
- Association between monocyte to high-density lipoprotein cholesterol ratio and telomere length: based on NHANES 1999-2002.BMC cardiovascular disorders · 2024Article
- Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression.bioRxiv : the preprint server for biology · 2024Article
- Precision Nutrition and Cardiovascular Disease Risk Reduction: the Promise of High-Density Lipoproteins.Current atherosclerosis reports · 2023Review
- Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis.RMD open · 2023Article
- Dyslipidemia in rheumatoid arthritis: the possible mechanisms.Frontiers in immunology · 2023Review
- High-density lipoprotein cholesterol efflux capacity in patients with obstructive sleep apnea and its relation with disease severity.Lipids in health and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Reduced levels of high-density lipoprotein (HDL) cholesterol correlate with increased risk for atherosclerotic cardiovascular diseases and HDL performs functions including reverse cholesterol transport, inhibition of lipid peroxidation, and suppression of inflammation, that would appear critical for cardioprotection. However, several large clinical trials utilizing pharmacologic interventions that elevated HDL cholesterol levels failed to provide cardioprotection to at-risk individuals. The reasons for these unexpected results have only recently begun to be elucidated. HDL cholesterol levels and HDL function can be significantly discordant, so that elevating HDL cholesterol levels may not necessarily lead to increased functional capacity, particularly under conditions that cause HDL to become oxidatively modified, resulting in HDL dysfunction. Here we review evidence that oxidative modifications of HDL, including by reactive lipid aldehydes generated by lipid peroxidation, reduce HDL functionality and that dicarbonyl scavengers that protect HDL against lipid aldehyde modification are beneficial in pre-clinical models of atherosclerotic cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.